Beyond aspirin and clopidogrel: Is there a need for additional antiplatelet therapy in ACS?

Lawrence Rajan, David J. Moliterno

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Dual antiplatelet therapy with aspirin and clopidogrel is a well-established standard of care for patients with acute coronary syndromes. Whether there are other drug strategies or therapies that will achieve fewer ischemic events, and at the same time be associated with fewer bleeding complications, is a question recurrently asked. Finding the appropriate pharmacologic calibration of antiplatelet potency and applying such a pharmacodynamic effect to all patients has only been partially successful. The shadow of this one-size-fits-all dilemma is now being recast with the arrival of newer antiplatelet agents, which are attempting to decouple antithrombotic potency from bleeding liability. Novel antiplatelet agents that act faster and have more consistent pharmacokinetics and higher potency are steadily emerging. Additionally, newer agents that target unique sites, such as the thrombin receptor on platelets, are being studied in large-scale clinical trials. Each of these new agents has the potential to extend net clinical benefits beyond those provided by aspirin and clopidogrel.

Original languageEnglish
Pages (from-to)303-311
Number of pages9
JournalCurrent Cardiology Reports
Issue number4
StatePublished - Aug 2011


  • Acute coronary syndromes
  • Antiplatelet therapy
  • Aspirin
  • Clopidogrel

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Beyond aspirin and clopidogrel: Is there a need for additional antiplatelet therapy in ACS?'. Together they form a unique fingerprint.

Cite this